- Home
- WKSP vs CANF Comparison
WKSP vs CANF Comparison
Compare WKSP & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WKSP
- CANF
- Stock Information
- Founded
- WKSP 2003
- CANF 1994
- Country
- WKSP United States
- CANF Israel
- Employees
- WKSP N/A
- CANF N/A
- Industry
- WKSP Auto Parts:O.E.M.
- CANF Biotechnology: Pharmaceutical Preparations
- Sector
- WKSP Consumer Discretionary
- CANF Health Care
- Exchange
- WKSP Nasdaq
- CANF Nasdaq
- Market Cap
- WKSP 14.7M
- CANF 14.8M
- IPO Year
- WKSP N/A
- CANF N/A
- Fundamental
- Price
- WKSP $3.38
- CANF $1.04
- Analyst Decision
- WKSP Strong Buy
- CANF Strong Buy
- Analyst Count
- WKSP 2
- CANF 2
- Target Price
- WKSP $15.75
- CANF $14.00
- AVG Volume (30 Days)
- WKSP 96.7K
- CANF 172.6K
- Earning Date
- WKSP 05-15-2025
- CANF 05-27-2025
- Dividend Yield
- WKSP N/A
- CANF N/A
- EPS Growth
- WKSP N/A
- CANF N/A
- EPS
- WKSP N/A
- CANF N/A
- Revenue
- WKSP $8,484,379.00
- CANF $674,000.00
- Revenue This Year
- WKSP $227.66
- CANF $461.72
- Revenue Next Year
- WKSP $52.23
- CANF N/A
- P/E Ratio
- WKSP N/A
- CANF N/A
- Revenue Growth
- WKSP 454.67
- CANF N/A
- 52 Week Low
- WKSP $2.44
- CANF $1.02
- 52 Week High
- WKSP $12.00
- CANF $4.69
- Technical
- Relative Strength Index (RSI)
- WKSP 56.44
- CANF 37.30
- Support Level
- WKSP $2.72
- CANF $0.98
- Resistance Level
- WKSP $3.47
- CANF $1.14
- Average True Range (ATR)
- WKSP 0.29
- CANF 0.06
- MACD
- WKSP 0.13
- CANF 0.01
- Stochastic Oscillator
- WKSP 88.17
- CANF 32.59
About WKSP Worksport Ltd.
Worksport Ltd through its subsidiaries, designs, develops, manufactures, and owns the IP on a variety of tonneau covers, solar integrations, and NP (Non-Parasitic), Hydrogen-based true green energy solutions for the sustainable, clean energy, and automotive industries. The company's product includes soft vinyl tonneau covers and hard aluminum tonneau covers. It operates in two reporting segments for financial reporting purposes: Hard Tonneau Covers and Soft Tonneau Covers. Geographically, the company operates in Canada, United States and Other Countries.
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).